TW201412310A - 調節ｈｓｐ９０活性之三唑化合物 - Google Patents

調節ｈｓｐ９０活性之三唑化合物 Download PDF

Info

Publication number
TW201412310A
TW201412310A TW102138982A TW102138982A TW201412310A TW 201412310 A TW201412310 A TW 201412310A TW 102138982 A TW102138982 A TW 102138982A TW 102138982 A TW102138982 A TW 102138982A TW 201412310 A TW201412310 A TW 201412310A
Authority
TW
Taiwan
Prior art keywords
optionally substituted
group
compound
alkyl
cancer
Prior art date
Application number
TW102138982A
Other languages
English (en)
Chinese (zh)
Inventor
Dinesh U Chimmanamanda
Joseph A Burlison
Wei-Wen Ying
li-jun Sun
Stefan Michael Schweizer
shi-jie Zhang
Zachary Demko
David James
Teresa Przewloka
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of TW201412310A publication Critical patent/TW201412310A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW102138982A 2007-02-08 2008-02-12 調節ｈｓｐ９０活性之三唑化合物 TW201412310A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90022507P 2007-02-08 2007-02-08
US99370907P 2007-09-13 2007-09-13

Publications (1)

Publication Number Publication Date
TW201412310A true TW201412310A (zh) 2014-04-01

Family

ID=39624217

Family Applications (2)

Application Number Title Priority Date Filing Date
TW102138982A TW201412310A (zh) 2007-02-08 2008-02-12 調節ｈｓｐ９０活性之三唑化合物
TW097104944A TWI417093B (zh) 2007-02-08 2008-02-12 調節ｈｓｐ９０活性之三唑化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW097104944A TWI417093B (zh) 2007-02-08 2008-02-12 調節ｈｓｐ９０活性之三唑化合物

Country Status (16)

Country Link
US (3) US8299107B2 (enExample)
EP (1) EP2118077B1 (enExample)
JP (1) JP5523839B2 (enExample)
KR (1) KR101567608B1 (enExample)
CN (1) CN101679319B (enExample)
AU (1) AU2008214279B2 (enExample)
BR (1) BRPI0807219A2 (enExample)
CA (1) CA2677481C (enExample)
DK (1) DK2118077T3 (enExample)
ES (1) ES2533356T3 (enExample)
IL (1) IL200241A0 (enExample)
MX (1) MX2009008547A (enExample)
NZ (1) NZ579403A (enExample)
PL (1) PL2118077T3 (enExample)
TW (2) TW201412310A (enExample)
WO (1) WO2008097640A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
WO2007139960A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007140002A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
DK2035396T3 (da) 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) * 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
EP2421833B1 (en) 2009-04-21 2015-01-14 Nerviano Medical Sciences S.r.l. Resorcinol derivatives as hsp90 inhibitors
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
ES2536980T3 (es) * 2010-12-20 2015-06-01 Sigma-Tau Research Switzerland S.A. Compuestos aril triazol con actividad antitumoral
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
AU2013239663A1 (en) * 2012-03-28 2014-10-09 Synta Pharmaceuticals Corp. Triazole derivatives as HSP90 inhibitors
US20150119395A1 (en) * 2012-04-04 2015-04-30 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
US20150283147A1 (en) * 2012-10-19 2015-10-08 Synta Pharmaceuticals Corp. Treating polycystic kidney disease with hsp90 inhibitory compounds
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
ES2674704T3 (es) * 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
JP2017523211A (ja) * 2014-08-04 2017-08-17 ドレクセル ユニバーシティ 新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法
US10568886B2 (en) 2014-09-12 2020-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Targeting Cyb5R3
AU2016208863B2 (en) * 2015-01-22 2020-01-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Resorcinol derivative as HSP90 inhibitor
EP3300500B9 (en) 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
CN106349233B (zh) * 2015-07-15 2021-06-01 上海翰森生物医药科技有限公司 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
CN107540624B (zh) * 2016-06-29 2020-06-16 广州市恒诺康医药科技有限公司 热休克蛋白抑制剂及其制备方法和应用
WO2018026811A2 (en) * 2016-08-01 2018-02-08 Ohio State Innovation Foundation Antifungal agents
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CA3061133A1 (en) 2017-04-27 2018-11-01 Codexis, Inc. Ketoreductase polypeptides and polynucleotides
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
CN114617888A (zh) * 2020-12-14 2022-06-14 江苏豪森药业集团有限公司 Egfr抑制剂治疗和预防眼部疾病或病况的医药用途
CN117462551B (zh) * 2023-12-27 2024-05-17 深圳国家感染性疾病临床医学研究中心 茚地那韦和/或其衍生物在制备抗结核药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
SE9603750D0 (sv) 1996-10-14 1996-10-14 Mydata Automation Ab Plockhuvud för komponentmonteringsmaskin
AR022230A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
ES2211420T3 (es) 1999-07-21 2004-07-16 F. Hoffmann-La Roche Ag Derivados de triazol.
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
JP2005513136A (ja) * 2001-12-21 2005-05-12 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド 酸化触媒としての金属錯体化合物の使用
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
ES2278346T3 (es) * 2003-08-20 2007-08-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals
EP1704856A4 (en) * 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
AU2005230867A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
EP1817295B1 (en) * 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) * 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CA2598899A1 (en) * 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha Novel hsp90 inhibitor
JP2008137894A (ja) * 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007088895A1 (ja) * 2006-01-31 2007-08-09 Mochida Pharmaceutical Co., Ltd. ３－アリールアミノ－１,２,４－トリアゾール誘導体
EP2038262B1 (en) * 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DK2035396T3 (da) * 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2007139952A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
CA2653222A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EA015710B1 (ru) 2006-07-14 2011-10-31 Хемоцентрикс, Инк. Триазолил фенилбензолсульфонамиды
CN102087451A (zh) * 2006-07-31 2011-06-08 夏普株式会社 有源矩阵基板、显示装置、和有源矩阵基板的检查方法
CA2659425C (en) * 2006-08-17 2017-06-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008024303A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
EP2193135A1 (en) 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
TW201011003A (en) * 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity

Also Published As

Publication number Publication date
AU2008214279B2 (en) 2012-08-16
BRPI0807219A2 (pt) 2015-05-26
JP5523839B2 (ja) 2014-06-18
US8748424B2 (en) 2014-06-10
NZ579403A (en) 2012-03-30
CA2677481A1 (en) 2008-08-14
CN101679319B (zh) 2014-07-09
KR101567608B1 (ko) 2015-11-09
PL2118077T3 (pl) 2015-05-29
TWI417093B (zh) 2013-12-01
US20140288301A1 (en) 2014-09-25
KR20090127402A (ko) 2009-12-11
EP2118077A2 (en) 2009-11-18
WO2008097640A2 (en) 2008-08-14
CN101679319A (zh) 2010-03-24
WO2008097640A8 (en) 2008-11-13
HK1137455A1 (en) 2010-07-30
CA2677481C (en) 2015-07-07
TW200843740A (en) 2008-11-16
DK2118077T3 (en) 2015-03-09
JP2010518085A (ja) 2010-05-27
US20110105483A1 (en) 2011-05-05
EP2118077B1 (en) 2014-12-24
MX2009008547A (es) 2010-01-15
AU2008214279A1 (en) 2008-08-14
IL200241A0 (en) 2010-04-29
ES2533356T3 (es) 2015-04-09
WO2008097640A3 (en) 2008-10-02
US8299107B2 (en) 2012-10-30
US20130072489A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
TWI417093B (zh) 調節ｈｓｐ９０活性之三唑化合物
TWI490212B (zh) 調節ｈｓｐ９０活性之三唑化合物
TWI438199B (zh) 調控ｈｓｐ９０活性的三唑化合物
US8524712B2 (en) Triazinone and diazinone derivatives useful as HSP90 inhibitors
US9206162B2 (en) Triazole compounds that modulate Hsp90 activity
US9156836B2 (en) Tricyclic triazole compounds that modulate HSP90 activity
ES2415234T3 (es) Compuestos de triazol que modulan la actividad Hsp90
US20150005299A1 (en) Pyrrole compounds that modulate hsp90 activity
JP2015515469A (ja) Ｈｓｐ９０阻害剤としてのトリアゾール誘導体
TW200904417A (en) Triazole compounds that modulate Hsp90 activity
HK1137455B (en) Triazole compounds that modulate hsp90 activity